|
|
|
Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024. |
|
|
|
Biopharma heavy hitters, including biotech and Big Pharma CEOs, members of Congress, investors, R&D leaders, academics, and U.S. health agency leaders, convened at the Galien Forum in New York City, offering tips and guidance for the leaders of tomorrow. |
|
|
|
Just under one-third of respondents who participated in ISR’s Oral Dosage Forms Market Outlook research shared that the category of familiarity/history of working together/prior positive experience covers the reasons behind their preferences. |
|
|
|
|
|
|
| Resin Vs. Protein A Membrane Purification | Common resin-based purification and Protein A membrane purification methods have distinct differences in terms of specificity, selectivity, purity, yield, cost, and time required. |
|
|
|
|
|
Inside you will find more on: - Funding Outlook
- Retaining Talent
- Outsourcing Tips
- Big Pharma Business Model
View the digital edition. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
